FDA continues crackdown on equine drugmakers

Shortly after warning three companies that they had violated FDA rules by making and marketing unapproved equine drugs, the FDA widened its lasso. The agency now says it has sent letters to 9 companies--all of which market drugs to treat ulcers in horses--warning that they are improperly selling the products without first obtaining FDA approval. Furthermore, the agency said, several of the drugs were either "subpotent," meaning they didn't include enough active ingredient, or "superpotent," containing too much of the advertised drug. The agency said the companies may be subject to injunctions or seizures and that anyone who bought the products should seek refunds. Release

Suggested Articles

The United Nations’ 2030 Agenda for Sustainable Development lays out a host of priorities including “food security and nutrition,” an ambitious plan to…

Starting next year, drugmakers that market antibiotics for food animals will face tough new FDA rules limiting their use. So now some pharma companies are…

The USDA plans to hold manufacturers of veterinary biotech drugs to new, strict standards on labeling. Although companies will have between four and six years…